Action 8: Support and fund clinical and implementation research to inform development and approval as well as use of paediatric formulations included in the PADO list.
Action 9: Only fund the procurement of drugs and formulations recommended by WHO that are included in the Optimal Formulary.
Action 21: Provide funding to support actions required for quickly introducing and scale-up new, optimal paediatric formulations.
46. Contribute to the funding of the secretariat of the Global Accelerator and its activities as outlined in the product portfolio of the GAP-f business plan
Proposal submitted to Elma to support GAP-f secretariat.